PERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE
Main Article Content
Abstract
Mature B cell disorders have recently become highly curable diseases thanks to the introduction of new treatment strategies; nonetheless, despite evidence of complete remission, many patients affected by lymphoma or myeloma eventually relapse and need salvage therapy. Minimal residual disease (MRD) detection and quantification is a powerful tool to evaluate treatment efficacy, to stratify patients, and to predict long-term outcome. In fact, in the current landscape of novel, highly efficacious but toxic and often costly targeted therapies, early identification of factors predictive of treatment response or refractoriness is the key to avoid overtreatment of patients and thus also to reduce costs for health care system.
In this article we reviewed the prognostic role of MRD in follicular lymphoma, mantle cell lymphoma and multiple myeloma. We analyzed published clinical studies and available methodologies, and we described the major ongoing studies of MRD-driven tailored treatment in these diseases. Finally, we discussed novel applications and techniques for MRD identification in hematologic malignancies and future directions of MRD-oriented research. In particular, we hypothesized some possible, next-generation, precision medicine trials in lymphoproliferative diseases based on the most promising currently available biomarkers.
Article Details
How to Cite
DOGLIOTTI, Irene; FERRERO, Simone.
PERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE.
Medical Research Archives, [S.l.], v. 5, n. 5, may 2017.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/1097>. Date accessed: 04 dec. 2024.
Keywords
Personalized medicine; lymphoma; myeloma; minimal residual disease;
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(1):9-29.
2. DL Longo AF, DL Kasper, SL Hauser, J Jameson, J Loscalzo. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.
3. DeVita VT, T S Lawrence, S A Rosenberg. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed2014.
4. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90.
5. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(15):3412-20.
6. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-65.
7. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(27):4555-62.
8. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65.
9. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(26):2863-9.
10. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. The Lancet Oncology. 2015;16(9):1111-22.
11. Hoster E. Minimal Residual Disease in Mantle Cell Lymphoma: Insights Into Biology and Impact on Treatment. ASH annual meeting abstracts. 2016.
12. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(24):3746-52.
13. Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119(9):2066-73.
14. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Annals of hematology. 2016;95(1):11-8.
15. Ferrero S, Drandi D, Mantoan B, Ghione P, Omede P, Ladetto M. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematological oncology. 2011;29(4):167-76.
16. Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future oncology. 2015;11(9):1327-42.
17. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine. 2014;370(12):1101-10.
18. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(8):1667-77.
19. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England journal of medicine. 2013;369(6):507-16.
20. Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia. The New England journal of medicine. 2015;373(6):584-6.
21. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2013;369(1):32-42.
22. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. The New England journal of medicine. 2015;372(15):1430-40.
23. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-6.
24. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. The New England journal of medicine. 2014;370(11):1008-18.
25. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2014;370(11):997-1007.
26. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine. 2016;374(4):311-22.
27. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16):3215-23.
28. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122(23):3759-66.
29. Ladetto M DMF, Benedetti F, Vitolo U, Patti C, Rambaldi A,, Pulsoni MM, Liberati A. M, Olivieri A, Gallamini A, Pogliani E,, Rota Scalabrini D CV, Di Raimondo F, Pavone F, Tucci A,, Cortelazzo S LA, Boccadoro M, Majolino I, Pileri A, M. Gianni A,, Passera R CP, and Tarella C. Prospective, multicenter randomized GITMO/IIL trial comparing intensive
(R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-13.
30. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(26):4365-70.
31. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-91.
32. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-11.
33. Gribben JG FA, Neuberg D, et al. . Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325(22):1525-33.
34. Weinberg OK, Ai WZ, Mariappan MR, Shum C, Levy R, Arber DA. ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. The Journal of molecular diagnostics : JMD. 2007;9(4):530-7.
35. Pott C, Bruggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods in molecular biology. 2013;971:175-200.
36. Pott C, Tiemann M, Linke B, Ott MM, von Hofen M, Bolz I, et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia. 1998;12(10):1630-7.
37. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687-93.
38. Ghione P, Monitillo, L., Barbero, D., Verardo, G., Drandi, D., Grimaldi, D., Genuardi, E., Mantoan, B., Cavallo, F., Vasta, M., Zaja, F., Visco, C., Cortelazzo, S., Ladetto, M., Ferrero, S. A Technical Comparison Between Igh And Bcl1/Igh Molecular Markers For Minimal Residual Disease Analysis In Mantle Cell Lymphoma. SIES meeting abstract. 2016.
39. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(12):2077-84.
40. Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia. 2015.
41. Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, et al. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget. 2016.
42. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007;13(9):1057-65.
43. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99(3):856-62.
44. Hirt C, Schuler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141(5):631-40.
45. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-23.
46. Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood. 2005;105(9):3428-33.
47. Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(36):6094-100.
48. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(8):1460-8.
49. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20(24):6398-405.
50. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10.
51. Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126(12):1407-14.
52. Boccomini C, Ladetto, M., Rigacci, L., Rattotti, S., Evangelista, A., Ferrero, S., Volpetti, S., Mantoan, B., Meli, E., Freilone, R., Corradini, P., Franceschetti, S., Rusconi, C., Stelitano, C., Dutto, F., Puccini, B., Bolis, S., Salvi, F., Fabbri, A., Billio, A., Tucci, A., Balzarotti, M., Vitolo, U. Sicurezza Ed Efficacia Di Una Breve Chemioimmunoterapia Di Prima Linea Con Rituximab, Bendamustina E Mitoxantrone (R-Bm) Seguita Da Consolidamento Con Rituximab Nei Pazienti Anziani Affetti Da Linfoma Follicolare In Stadio Avanzato: Risultati Finali Di Uno Studio Prospettico Di Fase Ii Della Fondazione Italiana Linfomi (FIL). SIE meeting abstracts. 2015.
53. Galimberti S EG, Ciabatti E, Grassi S, Metelli MR, Guerrini F et al. Galimberti S, Ercolano G, Ciabatti E, Grassi S, Metelli MR, Guerrini F et al. Rituximab-bendamustin: an effective treatment for minimal residual disease eradication in patients affected by follicular lymphoma. SIES meeting abstracts. 2016;Abstract C060.
54. Pott C, Belada, D., Danesi, N., Fingerle-Rowson, G., Gribben, J., Harbron, C., Hoster, E., Kahl, B. S., Mundt, K., Sebban, C., Sehn, L. H., Cheson, B. D. Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 2015.
55. Pott C, Hoster, E., Kehden, B., Unterhalt, M., Herold, M., van der Jagt, R. H., Janssens, A., Kneba, M., Mayer, J., Pocock, C., Danesi, N., Fingerle-Rowson, G., Harbron, C., Mundt, K., Marcus, R. E., Hiddemann, W. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. Blood. 2016;128:613.
56. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006;12(12):1270-6.
57. Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, et al. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of hematology. 2013;92(11):1503-11.
58. Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(10):2687-95.
59. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90(10):4212-21.
60. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102(2):749-55.
61. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96(3):864-9.
62. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107(6):2271-8.
63. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565-75.
64. Callanan MB, Delfau, M., Macintyre, E., Thieblemont, C., Oberic, L., Gyan, E., Bouabdallah, K., Gressin, R., Damaj, G., Casasnovas, O., Ribrag, V., Gimenez, E., Hermine, O., & Le Gouill, S. Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. Blood. 2015;126(23):338.
65. Cortelazzo S. MM, Ladetto M., Ferrero S., Ciccone G., Evangelista A., Mian M., Di Rocco A., Chiappella A., Rossi G., Re A, Zinzani P. L., Balzarotti M., Cavallo F., Rusconi C., Gotti M., Arcaini L., Gobbi M., Gomes M. Molinari A., Liberati A.M., Michieli M., Latte G., Cabras M. G., Novero D., Paulli M., Zamò A., Chilosi M., Federico M., Vitolo U. High Dose Sequential Chemotherapy With Rituximab And ASCT As First Line Therapy In Adult MCL Patients: Clinical And Molecular Response Of The MCL0208 Trial, A FIL Study. EHA Meeting abstracts. 2015.
66. Pott C, Macintyre E, Delfau-Larue M-H, Ribrag V, Unterhalt M, Kneba M, et al. MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network. Blood. 2014;124(21):147.
67. Kolstad A, Pedersen L. B., Eskelund, C. W., Husby, S., Grønbæk K., Jerkeman M., Laurell A., Räty, R., Elonen, E., Andersen, N.S., de Nully Brown, P., Geisler, C.H. Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years. ASH annual meeting abstracts. 2016;abstract n° 146.
68. Zaja F ea. Rituximab, lenalidomide, bendamustine second line therapy in mantle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL). ICML Abstracts 2015:014. ICML Abstracts 2015;014.
69. Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2016.
70. Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4. Blood. 2016.
71. Kaplan LD, Jung, S. H. , Bartlett, N. C. , Johnson, J. , Byrd, J. . Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance). ASH - Hematol Oncol,. 2013.
72. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(1):208-15.
73. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(11):2273-81.
74. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-7.
75. Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, et al. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica. 2012;97(6):849-53.
76. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-23.
77. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England journal of medicine. 2012;366(19):1759-69.
78. Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia. 2015;29(3):689-95.
79. Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013;19(7):1109-15.
80. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6):1299-307.
81. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-9.
82. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA oncology. 2015;1(6):746-54.
83. Avet-Loiseau H, Casneuf, T., Chiu, C., Laubach, J., , Lee J, Moreau, P., Plesner, T., Nahi, H.,, Khokhar NZ, Qi, M., Schecter, J., Carlton, V., Qin, X.,, Liu K, Wu, K., Zhuang, S. H., Ahmadi, T., Sasser, A. K.,, J. S-M. Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. ASH annual meeting abstracts. 2016.
84. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-22.
85. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(3):1110-7.
86. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(27):3059-68.
87. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging. 2010;37(10):1824-33.
88. Gallamini A, O'Doherty M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leukemia & lymphoma. 2011;52(4):583-6.
89. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leukemia & lymphoma. 2009;50(8):1257-60.
90. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109(9):1804-10.
91. Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, et al. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27(12):2149-60.
92. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5.
93. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, et al. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. The Journal of molecular diagnostics : JMD. 2015;17(6):652-60.
94. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-80.
95. Brüggemann M KH, Bartram J, et al. International multi-laboratory next-generation sequencing for MRD analysis in ALL. A pilot study by the Euroclonality-NGS Consortium. Haematologica. 2015;100(s1):P164:31.
96. de Vree PJ, de Wit E, Yilmaz M, van de Heijning M, Klous P, Verstegen MJ, et al. Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nat Biotechnol. 2014;32(10):1019-25.
97. Hottentot QP, van Min M, Splinter E, White SJ. Targeted Locus Amplification and Next-Generation Sequencing. Methods in molecular biology. 2017;1492:185-96.
98. Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(6):579-86.
99. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015;169(5):689-93.
100. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017.
101. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
102. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679-87.
103. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology. 2015;16(5):541-9.
104. Fontanilles M. MF, Bohers E., Viailly P., Bertrand, P., Dubois S., MareschaL S., Camus V., Veresezan E., Ruminy P., Tilly H., Laquerriere A., Picquenot J., Jardin F. Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma. ASH annual meeting abstracts. 2015.
105. Drandi D GE, Dogliotti I, Sciascia I, Guerrini F, Mantoan B, Gilestro M MV, Ghione P, Omedè P, Galimberti S, Orsucci L, Cavallo F,, Boccadoro M LM, Ferrero S. A Novel Digital PCR Assay For MYD88L265P Mutation Detection In Waldenström
Macroglobulinemia: Minimal Residual Disease Monitoring And Characterization On Circulating Free Dna. EHA Meeting abstracts. 2016.
106. Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.
2. DL Longo AF, DL Kasper, SL Hauser, J Jameson, J Loscalzo. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.
3. DeVita VT, T S Lawrence, S A Rosenberg. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed2014.
4. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90.
5. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(15):3412-20.
6. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-65.
7. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(27):4555-62.
8. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65.
9. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(26):2863-9.
10. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. The Lancet Oncology. 2015;16(9):1111-22.
11. Hoster E. Minimal Residual Disease in Mantle Cell Lymphoma: Insights Into Biology and Impact on Treatment. ASH annual meeting abstracts. 2016.
12. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(24):3746-52.
13. Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119(9):2066-73.
14. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Annals of hematology. 2016;95(1):11-8.
15. Ferrero S, Drandi D, Mantoan B, Ghione P, Omede P, Ladetto M. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematological oncology. 2011;29(4):167-76.
16. Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future oncology. 2015;11(9):1327-42.
17. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine. 2014;370(12):1101-10.
18. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(8):1667-77.
19. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England journal of medicine. 2013;369(6):507-16.
20. Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia. The New England journal of medicine. 2015;373(6):584-6.
21. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2013;369(1):32-42.
22. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. The New England journal of medicine. 2015;372(15):1430-40.
23. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-6.
24. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. The New England journal of medicine. 2014;370(11):1008-18.
25. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2014;370(11):997-1007.
26. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine. 2016;374(4):311-22.
27. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16):3215-23.
28. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122(23):3759-66.
29. Ladetto M DMF, Benedetti F, Vitolo U, Patti C, Rambaldi A,, Pulsoni MM, Liberati A. M, Olivieri A, Gallamini A, Pogliani E,, Rota Scalabrini D CV, Di Raimondo F, Pavone F, Tucci A,, Cortelazzo S LA, Boccadoro M, Majolino I, Pileri A, M. Gianni A,, Passera R CP, and Tarella C. Prospective, multicenter randomized GITMO/IIL trial comparing intensive
(R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-13.
30. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(26):4365-70.
31. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-91.
32. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-11.
33. Gribben JG FA, Neuberg D, et al. . Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325(22):1525-33.
34. Weinberg OK, Ai WZ, Mariappan MR, Shum C, Levy R, Arber DA. ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. The Journal of molecular diagnostics : JMD. 2007;9(4):530-7.
35. Pott C, Bruggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods in molecular biology. 2013;971:175-200.
36. Pott C, Tiemann M, Linke B, Ott MM, von Hofen M, Bolz I, et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia. 1998;12(10):1630-7.
37. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687-93.
38. Ghione P, Monitillo, L., Barbero, D., Verardo, G., Drandi, D., Grimaldi, D., Genuardi, E., Mantoan, B., Cavallo, F., Vasta, M., Zaja, F., Visco, C., Cortelazzo, S., Ladetto, M., Ferrero, S. A Technical Comparison Between Igh And Bcl1/Igh Molecular Markers For Minimal Residual Disease Analysis In Mantle Cell Lymphoma. SIES meeting abstract. 2016.
39. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(12):2077-84.
40. Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia. 2015.
41. Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, et al. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget. 2016.
42. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007;13(9):1057-65.
43. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99(3):856-62.
44. Hirt C, Schuler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141(5):631-40.
45. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-23.
46. Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood. 2005;105(9):3428-33.
47. Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(36):6094-100.
48. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(8):1460-8.
49. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20(24):6398-405.
50. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10.
51. Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126(12):1407-14.
52. Boccomini C, Ladetto, M., Rigacci, L., Rattotti, S., Evangelista, A., Ferrero, S., Volpetti, S., Mantoan, B., Meli, E., Freilone, R., Corradini, P., Franceschetti, S., Rusconi, C., Stelitano, C., Dutto, F., Puccini, B., Bolis, S., Salvi, F., Fabbri, A., Billio, A., Tucci, A., Balzarotti, M., Vitolo, U. Sicurezza Ed Efficacia Di Una Breve Chemioimmunoterapia Di Prima Linea Con Rituximab, Bendamustina E Mitoxantrone (R-Bm) Seguita Da Consolidamento Con Rituximab Nei Pazienti Anziani Affetti Da Linfoma Follicolare In Stadio Avanzato: Risultati Finali Di Uno Studio Prospettico Di Fase Ii Della Fondazione Italiana Linfomi (FIL). SIE meeting abstracts. 2015.
53. Galimberti S EG, Ciabatti E, Grassi S, Metelli MR, Guerrini F et al. Galimberti S, Ercolano G, Ciabatti E, Grassi S, Metelli MR, Guerrini F et al. Rituximab-bendamustin: an effective treatment for minimal residual disease eradication in patients affected by follicular lymphoma. SIES meeting abstracts. 2016;Abstract C060.
54. Pott C, Belada, D., Danesi, N., Fingerle-Rowson, G., Gribben, J., Harbron, C., Hoster, E., Kahl, B. S., Mundt, K., Sebban, C., Sehn, L. H., Cheson, B. D. Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 2015.
55. Pott C, Hoster, E., Kehden, B., Unterhalt, M., Herold, M., van der Jagt, R. H., Janssens, A., Kneba, M., Mayer, J., Pocock, C., Danesi, N., Fingerle-Rowson, G., Harbron, C., Mundt, K., Marcus, R. E., Hiddemann, W. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. Blood. 2016;128:613.
56. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006;12(12):1270-6.
57. Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, et al. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of hematology. 2013;92(11):1503-11.
58. Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(10):2687-95.
59. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90(10):4212-21.
60. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102(2):749-55.
61. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96(3):864-9.
62. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107(6):2271-8.
63. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565-75.
64. Callanan MB, Delfau, M., Macintyre, E., Thieblemont, C., Oberic, L., Gyan, E., Bouabdallah, K., Gressin, R., Damaj, G., Casasnovas, O., Ribrag, V., Gimenez, E., Hermine, O., & Le Gouill, S. Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. Blood. 2015;126(23):338.
65. Cortelazzo S. MM, Ladetto M., Ferrero S., Ciccone G., Evangelista A., Mian M., Di Rocco A., Chiappella A., Rossi G., Re A, Zinzani P. L., Balzarotti M., Cavallo F., Rusconi C., Gotti M., Arcaini L., Gobbi M., Gomes M. Molinari A., Liberati A.M., Michieli M., Latte G., Cabras M. G., Novero D., Paulli M., Zamò A., Chilosi M., Federico M., Vitolo U. High Dose Sequential Chemotherapy With Rituximab And ASCT As First Line Therapy In Adult MCL Patients: Clinical And Molecular Response Of The MCL0208 Trial, A FIL Study. EHA Meeting abstracts. 2015.
66. Pott C, Macintyre E, Delfau-Larue M-H, Ribrag V, Unterhalt M, Kneba M, et al. MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network. Blood. 2014;124(21):147.
67. Kolstad A, Pedersen L. B., Eskelund, C. W., Husby, S., Grønbæk K., Jerkeman M., Laurell A., Räty, R., Elonen, E., Andersen, N.S., de Nully Brown, P., Geisler, C.H. Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years. ASH annual meeting abstracts. 2016;abstract n° 146.
68. Zaja F ea. Rituximab, lenalidomide, bendamustine second line therapy in mantle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL). ICML Abstracts 2015:014. ICML Abstracts 2015;014.
69. Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2016.
70. Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4. Blood. 2016.
71. Kaplan LD, Jung, S. H. , Bartlett, N. C. , Johnson, J. , Byrd, J. . Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance). ASH - Hematol Oncol,. 2013.
72. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(1):208-15.
73. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(11):2273-81.
74. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-7.
75. Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, et al. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica. 2012;97(6):849-53.
76. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-23.
77. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England journal of medicine. 2012;366(19):1759-69.
78. Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia. 2015;29(3):689-95.
79. Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013;19(7):1109-15.
80. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6):1299-307.
81. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-9.
82. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA oncology. 2015;1(6):746-54.
83. Avet-Loiseau H, Casneuf, T., Chiu, C., Laubach, J., , Lee J, Moreau, P., Plesner, T., Nahi, H.,, Khokhar NZ, Qi, M., Schecter, J., Carlton, V., Qin, X.,, Liu K, Wu, K., Zhuang, S. H., Ahmadi, T., Sasser, A. K.,, J. S-M. Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. ASH annual meeting abstracts. 2016.
84. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-22.
85. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(3):1110-7.
86. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(27):3059-68.
87. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging. 2010;37(10):1824-33.
88. Gallamini A, O'Doherty M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leukemia & lymphoma. 2011;52(4):583-6.
89. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leukemia & lymphoma. 2009;50(8):1257-60.
90. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109(9):1804-10.
91. Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, et al. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27(12):2149-60.
92. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5.
93. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, et al. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. The Journal of molecular diagnostics : JMD. 2015;17(6):652-60.
94. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-80.
95. Brüggemann M KH, Bartram J, et al. International multi-laboratory next-generation sequencing for MRD analysis in ALL. A pilot study by the Euroclonality-NGS Consortium. Haematologica. 2015;100(s1):P164:31.
96. de Vree PJ, de Wit E, Yilmaz M, van de Heijning M, Klous P, Verstegen MJ, et al. Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nat Biotechnol. 2014;32(10):1019-25.
97. Hottentot QP, van Min M, Splinter E, White SJ. Targeted Locus Amplification and Next-Generation Sequencing. Methods in molecular biology. 2017;1492:185-96.
98. Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(6):579-86.
99. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015;169(5):689-93.
100. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017.
101. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
102. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679-87.
103. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology. 2015;16(5):541-9.
104. Fontanilles M. MF, Bohers E., Viailly P., Bertrand, P., Dubois S., MareschaL S., Camus V., Veresezan E., Ruminy P., Tilly H., Laquerriere A., Picquenot J., Jardin F. Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma. ASH annual meeting abstracts. 2015.
105. Drandi D GE, Dogliotti I, Sciascia I, Guerrini F, Mantoan B, Gilestro M MV, Ghione P, Omedè P, Galimberti S, Orsucci L, Cavallo F,, Boccadoro M LM, Ferrero S. A Novel Digital PCR Assay For MYD88L265P Mutation Detection In Waldenström
Macroglobulinemia: Minimal Residual Disease Monitoring And Characterization On Circulating Free Dna. EHA Meeting abstracts. 2016.
106. Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.